Previous Close | 71.74 |
Open | 71.88 |
Bid | 70.48 x 300 |
Ask | 0.00 x 0 |
Day's Range | 71.31 - 71.87 |
52 Week Range | 55.87 - 72.51 |
Volume | 12,359 |
Avg. Volume | 23,419 |
Net Assets | 218.76M |
NAV | 69.45 |
PE Ratio (TTM) | N/A |
Yield | 0.02% |
YTD Return | 8.30% |
Beta (3y) | 0.84 |
Expense Ratio (net) | 0.35% |
Inception Date | 2011-01-26 |
Novartis got government approval for a new cancer therapy. The treatment will cost a staggering $475,000, and it will help children and young adults with a certain type of Leukemia. Yahoo Finance's Seana Smith, Nicole Smith and Rick Newman react to what Wall Street is saying about the drug.
The healthcare sector is the second-best performer in the S&P 500 this year behind technology. Traditional, diversified healthcare exchange traded funds are delivering for investors. Just look at the Health ...
The price tag on Novartis' new cancer drug may be a bargain
Without intellectual property, there is no innovation—and as we’re rapidly discovering, no customers.
Based on the recommendations of 16 brokerage companies, around 63% (or ten) of the analysts provided a “buy” recommendation for Dentsply Sirona.
The broad markets have been relatively benign, but trading beneath the surface has been ferocious.
Yahoo Finance's LIVE market market coverage and analysis of stocks and bonds begins each day at 11:45 am ET.
Medical related ETFs have racked up healthy gains this year amid the ongoing quest for longer and healthier lives.
This was one of 2016's best healthcare ETFs, and the trend is continuing this year.